Vanderbilt University Medical Center
This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.
TXA is an antifibrinolytic agent that acts to decrease bleeding by stabilizing the fibrin matrix involved in the clotting cascade. The use of TXA, oral or intravenous, has been extensively used and described in the literature to prevent exsanguination in trauma and in various surgical procedures, as well as for heavy menstrual bleeding. It has been used in the perioperative period during various nasal and sinus surgery, and current research in rhinoplasty suggests that its use may decrease intraoperative bleeding and postoperative eye swelling and bruising. Currently, IV TXA is used at this i…
Inclusion Criteria: * Adults at least 18 years of age who elect to undergo cosmetic or functional open primary rhinoplasty with osteotomies (repositioning the nasal bones) by Drs. Yang or Patel at VUMC. * No other facial plastics procedure nor sinus surgery performed simultaneously * Lack all the below Exclusion Criteria Exclusion Criteria: * Known allergy to TXA (tranexamic acid) * Intracranial bleeding * Known defective color vision * History of venous or arterial thromboembolism * Active thromboembolic disease * Severe renal impairment (diagnosis of chronic kidney disease) * History of c…
1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
Arctuva estimate
Verify or correct the compensation shown for this listing.